Zogenix, Inc. And Mallinckrodt Pharmaceuticals Agree To End Co-Promotion For SUMAVEL® Dosepro® Effective January 31, 2014

Published: Jan 09, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, and Mallinckrodt (NYSE:MNK) announced today that the co-promotion of SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System will end on January 31, 2014. SUMAVEL DosePro is Zogenix's first commercial product and was launched in January 2010 for the acute treatment of migraine and cluster headache.

Help employers find you! Check out all the jobs and post your resume.

Back to news